Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine is a synthetic small molecule belonging to the class of benzene and substituted derivatives. It features a benzamidine core with a dioxaborolane substituent. The compound is primarily used as an experimental tool in biochemical research and has been identified as a potential inhibitor of serine proteases such as trypsin. Its mechanism involves mimicking the transition state or binding at the active site of target enzymes to inhibit their activity. There are no approved therapeutic indications for this compound; it is mainly utilized in laboratory settings for enzyme inhibition studies and structure-based drug design[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [4-(1,3,2-Dioxaborolan-2-Yloxy)Methyl]Benzamidine.